Creating vaccines to combat E. coli and other infectious diseases
Official title: Task V09: Development and Manufacture of Toxoid Fusion Master Banks
Funded at Idt Biologika Gmbh · NIH-10268398 · Data updated 2026-11-12
This study is working on creating new vaccines to help protect people from infections caused by E. coli, which could be especially helpful for patients looking for better ways to stay healthy and safe from serious illnesses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2020 |
| Award (this year) | $555,600 |
| NIH project number | 272201800011I-0-759302000003-1 |
| Project ID | NIH-10268398 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of E. coli infections or those in populations vulnerable to emerging infectious diseases.
✕Less likely to help
Patients who are not at risk for E. coli infections or those who have already been vaccinated against the targeted pathogens may not receive benefit from this research.
What this research studies
This research focuses on the development and manufacturing of vaccines and biologics aimed at preventing infectious diseases, particularly those caused by E. coli. It involves planning, optimizing, and producing vaccine candidates in compliance with regulatory standards for clinical trials. Patients may benefit from the introduction of new vaccines that could protect against serious infections and bioterrorism threats. The research includes comprehensive support for regulatory submissions to ensure safety and efficacy.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect patients from E. coli infections and other infectious diseases.
How similar studies have gone: Previous research has shown success in developing vaccines for infectious diseases, indicating a promising potential for this approach.
Where this research is happening
-
Idt Biologika Gmbh
Dessau-Rosslau, Germany Active
Researchers
- Principal investigator: Neubert, Andreas — Idt Biologika Gmbh
- Study coordinator: Neubert, Andreas
Related research
Other NIH-funded projects on the same topics.
-
Developing new vaccines for infectious diseases and bioterrorism
This study is all about creating new vaccines to help protect people from infectious diseases, including those that could come from bioterrorism or drug-resistant germs, so that patients can have better options for staying healthy.
-
Creating master cell banks for new SARS-CoV-2 vaccines
This study is working on creating special cell banks to help make better vaccines for COVID-19, which could lead to more effective options for patients in the future.
-
Creating materials for testing new influenza vaccines
This study is working on creating and improving materials for new flu vaccines, which could help keep you and others safer from the flu and similar illnesses.
-
Creating master cell banks for new SARS-CoV-2 vaccines
This study is working on creating special cell banks to help make better vaccines for COVID-19, so that patients can have more effective protection against the virus and its variants.
-
Creating vaccines and biologics to combat infectious diseases
This study is working on creating new vaccines to help protect people from infections like those caused by E. coli, so that patients can have better options for staying healthy and safe from serious diseases.
-
Developing a vaccine for Staphylococcus aureus
This study is working on creating a new vaccine to help protect people from Staphylococcus aureus infections, which can be tough to treat because the bacteria resist many antibiotics, and it aims to make this vaccine safe and effective for future use.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.